Investing

Earnings Previews: FedEx, Luminar, Nike, Celsion

Luminar

Luminar Technologies Inc. (NASDAQ: LAZR) has added about 19% to its share price since coming public in early December. In less than a week, shares traded up more than 80%. A week later, the stock traded flat to its opening day level, and it has bounced around ever since. Luminar makes lidar (light detection and ranging, or laser-light) systems for self-driving cars and trucks and, like every firm connected to electric and autonomous vehicles, 2020 was a wild ride. The company reports results after markets close Thursday.

Though not heavily followed yet, Luminar is expected to post a quarterly loss per share of $0.06 on sales of nearly $4 million. For the 2020 fiscal year, the consensus estimates call for a loss of $0.24 on sales of $15.1 million.

Analysts are positive on the stock, with Northland Securities boosting its rating from Market Perform to Outperform with a price target of $38 a share. The current share price is around $27.20, indicating a potential upside of about 35% to a consensus price target of $36.60. At the high target of $40, the potential upside is 47%.

The stock’s 52-week range is $9.45 to $47.80, although most of that was recorded before the reverse merger with blank-check company Gores Metropoulos. Average daily trading volume on the shares is nearly 8.5 million.

Celsion

Before markets open Friday, Celsion Corp. (NASDAQ: CLSN) is expected to report fourth-quarter and full-year 2020 results. Like all small-cap pharmaceuticals makers, Celsion stock swings wildly based on how new drugs are moving through the approval process. In late February, Celsion announced that it had received fast-track designation from the FDA for its ovarian cancer treatment. More than 340 million shares traded hands that day, boosting the stock’s 30-day volume average to nearly 20 million.

Analysts see a loss per share in the quarter of $0.13, some three cents worse than the year-ago loss. Revenue is pegged at $120,000. The numbers don’t improve with time, either. The good news is that the company has $8 billion in cash and short-term investments on hand and an equal amount of long-term debt.

Celsion only has two recent ratings, one a Strong Buy and the other a Buy. The consensus price target of $4.50 implies a potential upside of 105% to the current share price of around $2.20. At the high price target of $5.00, the implied upside is about 127%.